MDxHealth SA
MDXH Healthcare Diagnostics & Research
MDxHealth SA’s revenue for fiscal 2025 (year ended December 2025) was $107.9 million, up 19.8% from fiscal 2024. In the quarter to June 2026, revenue grew 12.0%, EPS fell 15.8%, free cash flow fell 200.2% and total debt rose 26.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow MDXH
MDxHealth SA (MDXH) EV/Sales
As of 16 October 2026, MDxHealth SA (MDXH) trades at a EV/Sales of 0.8×. Over the past ten years it has ranged from 0.0× (June 2023) to 3.1× (October 2025); the current reading is higher than 43% of that period. That is below the Diagnostics & Research industry median of 5.5× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.1× | 115.05% |
| FY2024 | 1.0× | (43.86%) |
| FY2023 | 1.8× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.9× | (42.70%) |
| Mar 2026 | 1.6× | (24.50%) |
| Dec 2025 | 2.1× | (25.42%) |
| Sep 2025 | 2.9× | 216.92% |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MBAI MBody AI Ltd. compare | n/m |
| PMD Psychemedics Corporation compare | 0.7× |
| MDXH MDxHealth SA | 0.8× |
| PRPO Precipio, Inc. compare | 1.3× |
| XGN Exagen Inc. compare | 2.6× |
| QUCY Quantum Cyber N.V compare | 8.4× |
| BNR Burning Rock Biotech Limited Sponsored ADR compare | 17.9× |
| MDXHF MedX Health Corp. compare | 29.4× |
| IMDX Insight Molecular Diagnostics Inc. compare | 55.7× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)